Results 101 to 110 of about 69,031,262 (351)
Annals of Internal Medicine, 2020 In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials.
Alice K. Pau +16 more
semanticscholar +1 more source
COVID-19: the epidemiology and treatment
British Journal of Hospital Medicine, 2020 After initially emerging in late 2019, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly to cause a global pandemic. SARS-CoV-2 is a betacoronavirus that is closely related to severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus ...
Liujing, Qu, Jinchun, Li, Hao, Ren
openaire +2 more sources
Design and analysis strategies for robust microbiome ageing research
FEBS Letters, EarlyView.The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik +5 more
wiley +1 more source
Treatment of patients with severe basic diseases combined with infection of novel coronavirus Omicron variant [PDF]
Zhenduanxue lilun yu shijian, 2022 Diagnosis and Treatment of COVID-19 from Expert Group of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
doaj +1 more source
Virology Journal, 2020 Background The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that enzyme.
D. Shrestha +5 more
semanticscholar +1 more source
A Comprehensive Summary of the Knowledge on COVID-19 Treatment
Aging and Disease, 2021 Currently, the world is challenged by the coronavirus disease 2019 (COVID-19) pandemic. Epidemiologists and researchers worldwide are invariably trying to understand and combat this precarious new disease.
Yu Peng +4 more
semanticscholar +1 more source
Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy
FEBS Letters, EarlyView.The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley +1 more source
Effective treatment of severe COVID-19 patients with tocilizumab
Proceedings of the National Academy of Sciences of the United States of America, 2020 Significance In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine
Xiaoling Xu +12 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche +10 more
wiley +1 more source
Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment
Bezmiâlem Science, 2020 The severe acute respiratory syndrome-coronaviruse-2 (SARSCoV- 2) genome is packaged in a helical nucleocapsid surrounded by a lipid bilayer. The virus envelope contains at least three viral proteins called spike protein (S), membrane protein (M) and ...
Sema ARISOY, Tansel ÇOMOĞLU
doaj +1 more source